Get started
Exelixis, Inc.Exelixis, Inc.Exelixis, Inc.

Exelixis, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastETFs

1EXEL chart


Full chart

1EXEL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪8.93 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
18.45
Basic EPS (TTM)
1.83 EUR
Net income (FY)
‪503.53 M‬ EUR
Revenue (FY)
‪2.09 B‬ EUR
Shares float
‪260.65 M‬
Beta (1Y)
1.17

Employees


Employees (FY)
‪1.15 K‬
Change (1Y)
−163 −12.44%
Revenue / Employee (1Y)
‪1.83 M‬ EUR
Net income / Employee (1Y)
‪439.00 K‬ EUR

About Exelixis, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Michael M. Morrissey
Website
exelixis.com
Headquarters
Alameda
Founded
1994
ISIN
US30161Q1040
FIGI
BBG01TNXQNJ8
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Check out other big names from the same industry as 1EXEL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1EXEL news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Sparks


Curated watchlists where 1EXEL is featured.

See all sparks 

Frequently Asked Questions


The current price of 1EXEL is 33.34 EUR — it has increased by 1.21% in the past 24 hours. Watch Exelixis, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange Exelixis, Inc. stocks are traded under the ticker 1EXEL.
1EXEL stock has fallen by −4.88% compared to the previous week, the month change is a −0.15% fall, over the last year Exelixis, Inc. has showed a 1.40% increase.
We've gathered analysts' opinions on Exelixis, Inc. future price: according to them, 1EXEL price has a max estimate of 51.08 EUR and a min estimate of 29.80 EUR. Watch 1EXEL chart and read a more detailed Exelixis, Inc. stock forecast: see what analysts think of Exelixis, Inc. and suggest that you do with its stocks.
1EXEL reached its all-time high on May 15, 2025 with the price of 42.61 EUR, and its all-time low was 29.27 EUR and was reached on Aug 21, 2025. View more price dynamics on 1EXEL chart.
See other stocks reaching their highest and lowest prices.
1EXEL stock is 1.20% volatile and has beta coefficient of 1.17. Track Exelixis, Inc. stock price on the chart and check out the list of the most volatile stocks — is Exelixis, Inc. there?
Today Exelixis, Inc. has the market capitalization of ‪8.93 B‬, it has increased by 2.79% over the last week.
Yes, you can track Exelixis, Inc. financials in yearly and quarterly reports right on TradingView.
Exelixis, Inc. is going to release the next earnings report on Nov 4, 2025. Keep track of upcoming events with our Earnings Calendar.
1EXEL earnings for the last quarter are 0.64 EUR per share, whereas the estimation was 0.57 EUR resulting in a 12.31% surprise. The estimated earnings for the next quarter are 0.59 EUR per share. See more details about Exelixis, Inc. earnings.
Exelixis, Inc. revenue for the last quarter amounts to ‪482.40 M‬ EUR, despite the estimated figure of ‪489.98 M‬ EUR. In the next quarter, revenue is expected to reach ‪505.51 M‬ EUR.
1EXEL net income for the last quarter is ‪156.92 M‬ EUR, while the quarter before that showed ‪147.54 M‬ EUR of net income which accounts for 6.36% change. Track more Exelixis, Inc. financial stats to get the full picture.
No, 1EXEL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 27, 2025, the company has ‪1.15 K‬ employees. See our rating of the largest employees — is Exelixis, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Exelixis, Inc. EBITDA is ‪663.44 M‬ EUR, and current EBITDA margin is 33.14%. See more stats in Exelixis, Inc. financial statements.
Like other stocks, 1EXEL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Exelixis, Inc. stock right from TradingView charts — choose your broker and connect to your account.